Companies › Newron Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 3; Psychiatry; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Evenamide Sodium channel alpha subunit blocker | Ion channels | Phase 3 | Treatment-resistant Schizophrenia | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07184619 | Evenamide | Phase 3 | Treatment-resistant Schizophrenia | Psychiatry | Mar 2027 |
Xenon Pharmaceuticals HB BioTech Gedeon Richter Cybin IRL Beijing Union Pharmaceutical Factory
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.